samedan logo

 
 
spacer
home > ebr > autumn 2001 > personalised medicine draws nearer
PUBLICATIONS
European Biopharmaceutical Review

Personalised Medicine Draws Nearer

What's your broad perspective on the uptake of pharmacogenomics to-date as a drug development activity, and how significant do you think this is for the industry? First of all, we have long believed that pharmacogenomics is really the first application of the genomics revolution. In other words, the first key products that will come out of the whole genomics field will be in the form of molecular diagnostics, based on determining genetic variability in patient response to drugs. We believe the pharmaceutical industry is now moving rapidly to incorporate pharmacogenomics across drug development activities. For example, in most clinical trials, DNA is being isolated and stored, to be queried later against genetic markers identifying which patients are responding to drugs.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Taylor Crouch joined Variagenics, Inc. in April 1999 with a distinguished track record in pharmaceutical marketing and clinical development. Formerly Senior Vice President for worldwide marketing and strategic development at the multinational CRO, PAREXEL International Corporation, he also spent 10 years in the pharmaceutical and device industries in new product development marketing at Schering Plough International, Pfizer International and Johnson & Johnson's Critikon Division. A man with a clear vision for the future of pharmacogenomics in the development and commercialisation of new medicines, Crouch spoke with Helen Abbott, Editor of EBR, about this brave new world.
spacer
Taylor Crouch
spacer
spacer
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Orbit Discovery Awarded Innovate UK Grant to Expand High Throughput Cell-Based Functional Screening Platform Capabilities in Peptide Drug Discovery

Oxford, United Kingdom, 13th June, 2022: Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the UK’s innovation agency. Totalling £472,000, the grant will facilitate the implementation of droplet-based microfluidics for cell-based functional screening and significantly expand the capabilities and throughput of Orbit’s peptide display platform. The project aims to advance the discovery of peptide therapeutic candidates including the most challenging of drug targets by improving overall process efficiency whilst reducing the risk and associated costs.
More info >>

White Papers

Advances in Aseptic Blow-Fill-Seal Processing of Pharmaceutical Liquids Improve Product Integrity and Patient Safety

Weiler Engineering, Inc

The latest improvements in aseptic blow-fill-seal technology are providing more streamlined automation of critical B/F/S processing areas, while limiting human intervention and effectively reducing airborne microbial bioburden and particulate levels, and enhancing sterility assurance and patient safety.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement